Novo Nordisk is increasing its efforts to promote its weight problems drug Wegovy on to sufferers, hanging agreements with telehealth firms together with Hims & Hers, Ro, and LifeMD.
Novo final month launched a brand new direct-to-consumer web site referred to as NovoCare Pharmacy that sells Wegovy, which usually carries an inventory value of about $1,350 a month, at $499 a month to sufferers who’re paying on their very own with out insurance coverage. With the brand new offers, sufferers can order this lower-priced Wegovy straight on the telehealth firms’ websites and get the remedy delivered to their properties.
Novo is following within the footsteps of competitor Eli Lilly, which started promoting its weight problems drug Zepbound with telehealth firms at a decrease value final 12 months.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
